Sugi Predict

Sugi Predict / Compounds / SCHEMBL930113

SCHEMBL930113

SCHEMBL930113

CCOC(=O)c1ccc[nH]c1=O

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.61
▸ KDM4E B2RXH2 3/20 0.56
▸ NPC1 O15118 4/20 0.56
▸ RAB9A P51151 4/20 0.56
▸ NAPRT Q6XQN6 1/20 0.55
▸ ALDH1A1 P00352 3/20 0.54
▸ GAA P10253 1/20 0.54
▸ RECQL P46063 1/20 0.54
▸ MAPT P10636 1/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ SMN1; SMN2 Q16637 3/20 0.53
▸ HSD17B10 Q99714 1/20 0.53
▸ CLEC4M Q9H2X3 1/20 0.52
▸ HPGD P15428 1/20 0.52
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4428342 0.98 TSHR (0.59) TSHRKDM4ENPC1RAB9ANAPRT
SCHEMBL11542451 0.84 CDC25B (0.50) TSHRKDM4ENPC1RAB9AALDH1A1
SCHEMBL11545855 0.81 CDC25B (0.47) TSHRKDM4ENPC1RAB9AALDH1A1
SCHEMBL680683 0.80 NAPRT (0.60) TSHRKDM4ENAPRTALDH1A1GAA
SCHEMBL6219929 0.79 ALDH1A1 (0.56) TSHRKDM4ENPC1ALDH1A1GAA
Hydrochloric Acid SCHEMBL4428793 0.79 NAPRT (0.58) TSHRKDM4ENAPRTALDH1A1GAA
SCHEMBL754622 0.78 ALDH1A1 (0.55) TSHRKDM4ENPC1ALDH1A1GAA
Diethyl Phthalate SCHEMBL29404255 0.77 TSHR (1.00) TSHRKDM4ENPC1ALDH1A1MAPT
Diethyl Phthalate SCHEMBL22296 0.77 TSHR (1.00) TSHRKDM4ENPC1ALDH1A1MAPT
Diethyl Phthalate SCHEMBL5306972 0.77 TSHR (1.00) TSHRKDM4ENPC1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119998271-A Pyridone compound and preparation method and application thereof 深圳信立泰药业股份有限公司 2025-05-13 — — CN disclosed
WO-2025067126-A1 PYRIDONE COMPOUNDS AND PREPARATION METHOD THEREFOR, AND APPLICATION 深圳信立泰药业股份有限公司 2025-04-03 — — WO disclosed
EP-3843850-B1 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC (US) 2023-11-15 — — EP disclosed
US-11780835-B2 Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases ARRAY BIOPHARMA INC. (US) 2023-10-10 — — US disclosed
CN-113195471-B Polysubstituted pyridone derivative and application thereof in medicine 苏州浦合医药科技有限公司 2023-05-02 — — CN disclosed
WO-2023020479-A1 PARP7 INHIBITOR AND APPLICATION THEREOF 重庆华森制药股份有限公司 2023-02-23 — — WO disclosed
US-20230011441-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC. (US) 2023-01-12 — — US disclosed
CN-113195471-A Polysubstituted pyridone derivative and application thereof in medicine 北京越之康泰生物医药科技有限公司 2021-07-30 — — CN disclosed
US-10899772-B2 IRAK4 modulators GENENTECH, INC. (US) 2021-01-26 — — US disclosed
EP-3642201-A1 ISOINDOLINONE DERIVATIVES AS IRAK4 MODULATORS H. Hoffnabb-La Roche Ag (CH) 2020-04-29 — — EP disclosed
US-6015820-A VIRICIDES; AIDS TREATMENT CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2000-01-18 — — US disclosed
EP-0843663-A1 4-ARYL-THIO-PYRIDIN-2(1H)-ONES, DRUGS CONTAINING SAME, AND USES THEREOF FOR TREATING HIV-RELATED DISEASES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 1998-05-27 — — EP disclosed
WO-1997005113-A1 4-ARYL-THIO-PYRIDIN-2(1H)-ONES, DRUGS CONTAINING SAME, AND USES THEREOF FOR TREATING HIV-RELATED DISEASES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 1997-02-13 — — WO disclosed
EP-0265126-B1 Process for the preparation of fused pyridine compounds UNIV PRINCETON (US) 1994-04-13 — — EP disclosed
US-4988813-A Process for the preparation of fused pyridine compounds THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1991-01-29 — — US disclosed
US-4902796-A 6-alkenyl and ethynyl derivatives of 2-amino-4-hydroxypyrido[2,3-d]pyrimidines THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1990-02-20 — — US disclosed
US-4818819-A Process for the preparation of fused pyridine compounds THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1989-04-04 — — US disclosed
EP-0265126-A2 Process for the preparation of fused pyridine compounds THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1988-04-27 — — EP disclosed
US-4336256-A TREATMENT OF ANOXIA, DEPRESSION AND IN PSYCHOTROPIC THERAPY SYNTHELABO (FR) 1982-06-22 — — US disclosed
US-4272539-A ANOXIA, ANTIDEPRESSANTS SYNTHELABO (FR) 1981-06-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230011441-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES RET, MERTK, MET TSHR 526/4885KDM4E 935/4885NPC1 4245/4885
US-10899772-B2 IRAK4 modulators IRAK4, IRAK1, IRAK2 TSHR 3364/4885KDM4E 761/4885NPC1 1149/4885
US-11780835-B2 Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases RET, MERTK, MET TSHR 526/4885KDM4E 935/4885NPC1 4245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.